The Bundibugyo strain of the Ebola virus: What do we know?

Bundibugyo kills 30%-40% infected, less lethal than Zaire strain, fatal in up to 90% worldwide

A woman washes her hands at the Grande Barrier border following confirmation of an Ebola outbreak involving the Bundibugyo strain, at the border crossing point between Congo and Rwanda, in Goma, Democratic Republic of Congo May 18, 2026.PHOTO: REUTERS

A rare strain of Ebola has prompted the World Health Organisation (WHO) to declare a public health emergency of international concern. Most of the cases have occurred in the Democratic Republic of Congo (DRC), with more than 100 suspected deaths and nearly 400 suspected infections as of Monday.

Here is what we know about ​this strain of the Ebola virus, known as Bundibugyo.

What is Bundibugyo Ebola?

The current Ebola outbreak — so far limited to the Democratic Republic of ‌the Congo and Uganda — is due to a rare strain of the virus known as Bundibugyo, named after Uganda’s Bundibugyo province, where it was first identified during an outbreak in 2007-2008. A second Bundibugyo outbreak occurred in 2012 in the DRC.

A Congolese health worker checks the temperature to screen a traveller at the Grande Barrier border following confirmation of an Ebola outbreak involving the Bundibugyo strain, at the border crossing point between Congo and Rwanda, in Goma, Democratic Republic of Congo, May 18, 2026.PHOTO: REUTERS

Bundibugyo kills 30% to 40% of infected people, making it less lethal than the more common Zaire strain, which causes death in up to 90%, according ​to a global study published in 2024.

Bundibugyo is one of the four species of the ebolavirus genus that cause life-threatening illness in humans. All Ebola viruses are ​transmitted through direct contact with the bodily fluids of infected animals or humans or objects contaminated with such fluids.

Read More: Health workers race to contain Congo's fast-spreading Ebola outbreak

Body fluid transmission ⁠is a particular risk for hospital workers. A US doctor working in the DRC has been infected in the current outbreak.

According to the WHO, ebolaviruses initially cause ​flu-like symptoms, including fever, fatigue, malaise, muscle pain, headache and sore throat, that can start suddenly, followed by vomiting and diarrhoea, and eventually by internal and external bleeding and ​multi-organ failure.

Are there treatments for Bundibugyo?

There are no approved vaccines or drugs for Bundibugyo ebolavirus. Emergency use authorisation would be necessary for the deployment of any experimental treatments or existing treatments that have been effective against other strains.

Also Read: WHO declares Ebola outbreak in Congo, Uganda

Potential candidates that have helped to control Bundibugyo in trials in non-human primates include Merck’s Ervebo, Mapp Biopharmaceutical's MBP 134 and Auro Vaccines’ VesiculoVax.

NanoViricide said its experimental antiviral drug ​NV-387, currently in clinical trials against mpox, could be effective against the Bundibugyo strain. It mimics the immune cell surface proteins to which all ebolaviruses attach themselves ​and could thereby act as a decoy to "soak up" the virus and prevent it from attaching to healthy cells.

Load Next Story